Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases

摘要

Summary What is known and the objective Low‐grade evidence supports the use of newer biologics for otherwise refractory juvenile idiopathic arthritis (JIA)‐associated uveitis, such as tocilizumab. Case summary This report details the cases of two adolescents whose severe JIA‐associated uveitis was unresponsive to the first‐line therapeutic approach. Tocilizumab therapy led to the remission of uveitis after a mean time of 3?weeks, and methotrexate was safely discontinued 1.5?years later. What is new and conclusion To our knowledge, these are the first reports of successful methotrexate withdrawal during tocilizumab treatment of JIA‐associated uveitis. The administration of tocilizumab without methotrexate could be considered in patients with JIA‐associated uveitis unresponsive to conventional therapy.